Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
JD Health International Inc. (JDHIF)
Beijing, CN
JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People's Republic of China. It provides online medical consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services, as well as internet healthcare, health management, intelligent healthcare, advertising, and technical services. The company also offers home care services, including wound care, blood tests and diagnostics, post-operative care, and medical escort; online medical insurance payment services; and smart healthcare and digital health solutions. In addition, it provides online marketing services to advertisers; and online shopping and hospital services. Further, the company offers smart monitoring and respiratory therapy devices; senior-oriented medical devices; home medical device set-up and support services, including blood glucose meters and oxygen generators; and rapid testing products. Additionally, it provides traditional Chinese medicine (TCM) wellness and professional orthopedic services, as well as operates offline examination and polyclinic centers that offers convenient and professional healthcare services. The company offers pharmaceutical and healthcare products through direct sales, and online marketplace and on-demand retail businesses. It serves pharmaceutical and healthcare product companies. JD Health International Inc. was founded in 2014 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -22.82% | -33.14% | -22.82% | +81.11% | -5.65% | -61.00% | -67.72% | -67.72% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Healthcare Information Services: +14.2%+23.0% ★ Q4'25: +42.0% (vs Q4'23)
-
EPS growth Medical - Healthcare Information Services: +43.1%+22.0% Q4'25: +366.7% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+9.2% Q4'25: +0.0% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+5.2% Q4'25: +4.6% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%+24.0% ★ Q4'25: +44.1% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+1.1% Q4'25: +0.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.16× ★ Q4'25: 0.08× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 18 Rev. Ana. 1 EPS Ana. |
Dec 2027 18 Rev. Ana. 1 EPS Ana. |
Dec 2028 8 Rev. Ana. 1 EPS Ana. |
Dec 2029 11 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
19.38B
est: 18.72B (+3.5%)
|
30.68B
est: 29.79B (+3.0%)
|
46.74B
est: 44.14B (+5.9%)
|
53.53B
est: 53.23B (+0.6%)
|
58.16B
est: 57.77B (+0.7%)
|
71.55B
est: 72.02B (-0.7%)
|
89.32B
87.24B – 90.73B
+24.0% YoY
|
102.93B
96.08B – 107.57B
+15.2% YoY
|
116.67B
111.24B – 120.34B
+13.3% YoY
|
133.51B
127.30B – 137.71B
+14.4% YoY
|
| EBITDA |
-17.04B
est: -2.93B (-480.6%)
|
-832.32M
est: -4.67B (+82.2%)
|
943.79M
est: -6.92B (+113.6%)
|
858.31M
est: -8.34B (+110.3%)
|
5.02B
est: 1.74B (+187.8%)
|
3.97B
est: 2.17B (+82.7%)
|
2.70B
2.63B – 2.74B
+24.0% YoY
|
3.11B
2.90B – 3.25B
+15.2% YoY
|
3.52B
3.36B – 3.63B
+13.3% YoY
|
4.03B
3.84B – 4.16B
+14.4% YoY
|
| EBIT |
-17.07B
est: -2.99B (-471.1%)
|
-895.49M
est: -4.76B (+81.2%)
|
704.91M
est: -7.05B (+110.0%)
|
630.85M
est: -8.50B (+107.4%)
|
4.80B
est: 1.55B (+210.1%)
|
3.70B
est: 1.93B (+91.5%)
|
2.40B
2.34B – 2.43B
+24.0% YoY
|
2.76B
2.58B – 2.89B
+15.2% YoY
|
3.13B
2.98B – 3.23B
+13.3% YoY
|
3.58B
3.41B – 3.69B
+14.4% YoY
|
| Net Income |
-17.23B
est: -11.41B (-51.0%)
|
-1.07B
est: -244.84M (-338.5%)
|
380.11M
est: 934.34M (-59.3%)
|
2.14B
est: 2.01B (+6.7%)
|
4.16B
est: 3.07B (+35.5%)
|
5.24B
est: 5.06B (+3.6%)
|
6.06B
5.69B – 6.31B
+19.8% YoY
|
7.50B
7.05B – 7.81B
+23.8% YoY
|
8.96B
8.42B – 9.33B
+19.4% YoY
|
10.71B
10.06B – 11.14B
+19.4% YoY
|
| SGA |
3.96B
est: 2.66B (+48.6%)
|
7.67B
est: 4.24B (+81.1%)
|
4.35B
est: 6.28B (-30.7%)
|
4.65B
est: 7.57B (-38.5%)
|
4.47B
est: 7.84B (-43.0%)
|
12.30B
est: 9.78B (+25.8%)
|
12.12B
11.84B – 12.32B
+24.0% YoY
|
13.97B
13.04B – 14.60B
+15.2% YoY
|
15.84B
15.10B – 16.33B
+13.3% YoY
|
18.12B
17.28B – 18.69B
+14.4% YoY
|
| EPS |
-5.41
est: -3.61 (-49.8%)
|
-0.35
est: -0.08 (-351.8%)
|
0.12
est: 0.30 (-59.4%)
|
0.69
est: 0.63 (+8.7%)
|
1.32
est: 0.96 (+37.4%)
|
1.68
est: 1.58 (+6.2%)
|
1.90
1.78 – 1.97
+19.8% YoY
|
2.35
2.21 – 2.44
+23.8% YoY
|
2.80
2.63 – 2.92
+19.4% YoY
|
3.35
3.15 – 3.49
+19.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco S&P Emerging Markets Momentum ETF EEMO | 0.10% | 25.9K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cao Dong | Chief Executive Officer & Director | 126.1K | male |
| Deng Hui | Chief Financial Officer | — | female |
| Ming King Chiu FCIS | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JDHIF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
